Literature DB >> 32164372

mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice.

Xinyu Zhuang1, Yanxin Qi2, Maopeng Wang3, Ning Yu4, Fulong Nan5, He Zhang1, Mingyao Tian1, Chang Li1, Huijun Lu1, Ningyi Jin1.   

Abstract

The design of the mRNA vaccine involves the selection of in vitro transcription (IVT) systems and nonviral delivery vectors. This study aimed to verify the effect of 5' and 3' untranslated region (UTR) sequences on the translation efficiency of mRNA. Three modes of IVT-mRNA systems (IVT-mRNA-n1/n2/n3) with diverse UTRs were constructed, and EGFP (enhanced green fluorescent protein) and HA (hemagglutinin) gene of H3N2 influenza virus were introduced into each of them. The results showed that the mode of 5' and 3' UTRs originating from human β-globulin was better than the mode of UTRs from human α-globulin, and the n3 mode was the best. mEGFP-n3, mH3HA-n3, and mLuciferease-n3 were prepared to compare the effect of cationic lipid nanoparticle (LNP) with that of mannose-conjugated LNP (LNP-Man) on the efficiency of gene delivery. The results showed that the effect of LNP-Man was better than that of LNP both in vitro and in vivo. Choosing appropriate ligands might help in vaccine design. After selecting the IVT-mRNA-n3 system and delivery vectors, mRNA vaccines were constructed against the H1N1 influenza virus, and C57BL/6 mice were immunized through intranasal administration. The results showed that mRNA vaccines could elicit both humoral and cellular immune responses and completely protect mice from the tenfold LD50 H1N1 influenza virus challenge.

Entities:  

Keywords:  cationic lipid nanoparticles; influenza A H1N1 virus; intranasal administration; mRNA vaccine; mannose

Year:  2020        PMID: 32164372     DOI: 10.3390/vaccines8010123

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  23 in total

1.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 2.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

Review 3.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

4.  Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection.

Authors:  Tao Chen; Shuo Zhu; Ning Wei; Zikai Zhao; Junjun Niu; Youhui Si; Shengbo Cao; Jing Ye
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

Review 5.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

Review 6.  Promising Adjuvants and Platforms for Influenza Vaccine Development.

Authors:  Wandi Zhu; Chunhong Dong; Lai Wei; Bao-Zhong Wang
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

Review 7.  Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines.

Authors:  Iman M Alfagih; Basmah Aldosari; Bushra AlQuadeib; Alanood Almurshedi; Mariyam M Alfagih
Journal:  Pharmaceutics       Date:  2020-12-30       Impact factor: 6.321

Review 8.  Nanomaterial Delivery Systems for mRNA Vaccines.

Authors:  Michael D Buschmann; Manuel J Carrasco; Suman Alishetty; Mikell Paige; Mohamad Gabriel Alameh; Drew Weissman
Journal:  Vaccines (Basel)       Date:  2021-01-19

Review 9.  Advances in gene-based vaccine platforms to address the COVID-19 pandemic.

Authors:  Deborah Pushparajah; Salma Jimenez; Shirley Wong; Hibah Alattas; Nafiseh Nafissi; Roderick A Slavcev
Journal:  Adv Drug Deliv Rev       Date:  2021-01-07       Impact factor: 17.873

Review 10.  Self-assembled mRNA vaccines.

Authors:  Jeonghwan Kim; Yulia Eygeris; Mohit Gupta; Gaurav Sahay
Journal:  Adv Drug Deliv Rev       Date:  2021-01-02       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.